Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Apr 14;4(4):CD009683.
doi: 10.1002/14651858.CD009683.pub2.

Topiramate for essential tremor

Elisa Bruno  1 , Alessandra Nicoletti  1 , Graziella Quattrocchi  1 , Roberta Allegra  2 , Graziella Filippini  3 , Carlo Colosimo  4 , Mario Zappia  1
Affiliations
Meta-Analysis

Topiramate for essential tremor

Elisa Bruno et al. Cochrane Database Syst Rev. .

Abstract

Background: Essential tremor (ET) is one of the most common movement disorders. The management is primarily based on pharmacological agents and in clinical practice propranolol and primidone are considered the first-line therapy. However, these treatments can be ineffective in 25% to 55% of people and are frequently associated with serious adverse events (AEs). For these reasons, it is worthwhile evaluating other treatments for ET. Topiramate has been suggested as a potentially useful agent for the treatment of ET but there is uncertainty about its efficacy and safety.

Objectives: To assess the efficacy and safety of topiramate in the treatment of ET.

Search methods: We carried out a systematic search without language restrictions to identify all relevant trials in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (January 1966 to January 2017), Embase (January 1988 to January 2017), National Institute for Health and Care Excellence (1999 to January 2017), ClinicalTrials.gov (1997 to January 2017) and World Health Organization International Clinical Trials Registry Platform (ICTRP; 2004 to January 2017). We searched BIOSIS Citation Index (2000 to January 2017) for conference proceedings. We handsearched grey literature and the reference lists of identified studies and reviews.

Selection criteria: We included all randomised controlled trials (RCTs) of topiramate versus placebo/open control or any other treatments. We included studies in which the diagnosis of ET was made according to accepted and validated diagnostic criteria. We excluded studies conducted in people presenting with secondary forms of tremor or reporting only neurophysiological parameters to assess outcomes.

Data collection and analysis: Two review authors independently collected and extracted data using a data collection form. We assessed the risk of bias and the quality of evidence. We used a fixed-effect meta-analysis for data synthesis.

Main results: This review included three trials comparing topiramate to placebo (309 participants). They were all at high overall risk of bias. The quality of evidence ranged from very low to low. Compared to placebo, participants treated with topiramate showed a significant improvement in functional disability and an increased risk of withdrawal (risk ratio (RR) 1.78, 95% confidence interval (CI) 1.23 to 2.60). There were more AEs for topiramate-treated participants, particularly paraesthesia, weight loss, appetite decrease and memory difficulty.

Authors' conclusions: This systematic review highlighted the presence of limited data and very low to low quality evidence to support the apparent efficacy and the occurrence of treatment-limiting AEs in people with ET treated with topiramate. Further research to assess topiramate efficacy and safety on ET is needed.

PubMed Disclaimer

Conflict of interest statement

EB: none.

AN: none.

GQ: none.

RA: none.

GF: none.

CC: none.

MZ: none.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.1 Functional disability component related to tremor.
5
5
Forest plot of comparison: 1 Topiramate versus placebo/open control, outcome: 1.2 Withdrawals.
1.1
1.1. Analysis
Comparison 1 Topiramate versus placebo/open control, Outcome 1 Functional disability component related to tremor.
1.2
1.2. Analysis
Comparison 1 Topiramate versus placebo/open control, Outcome 2 Withdrawals.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Carrasco Vargas 2011 {published data only}
    1. Carrasco Vargas H, Castellanos Rodriguez J, Aceves Rodriguez R. Prospective double blind study of the use of topiramate vs. placebo in the treatment of essential tremor [Estudio prospectivo doble ciego del uso de topiramato vs. placebo en el tratamiento de temblor esencial]. Neurologia, Neurocirugia, Psiquiatria 2011;44:1‐5.
Connor 2008 {published data only}
    1. Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double‐blind, placebo‐controlled, crossover trials. Clinical Neuropharmacology 2008;31(2):97‐103. - PubMed
Ondo 2006 {published data only}
    1. Ondo WG, Jankovic J, Connor JS, Pahwa R, Elble R, Stacy MA, Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double‐blind, placebo‐controlled trial. Neurology 2006;66:672‐7. - PubMed

References to studies excluded from this review

Bermejo 2007 {published data only}
    1. Bermejo PE, Dorado R. Topiramate in refractory essential tremor. Revista Neurologia 2007;45(3):188‐9. - PubMed
Frima 2006 {published data only}
    1. Frima N, Grünewald RA. A double‐blind, placebo‐controlled, crossover trial of topiramate in essential tremor. Clinical Neuropharmacology 2006;29(2):94‐6. - PubMed
Gálvez‐Jimenez 2000 {published data only}
    1. Gálvez‐Jiménez N, Hargreave M. Topiramate and essential tremor. Annals of Neurology 2000;47(6):837‐8. - PubMed
Gatto 2003 {published data only}
    1. Gatto EM, Roca MC, Raina G, Micheli F. Low doses of topiramate are effective in essential tremor: a report of three cases. Clinical Neuropharmacology 2003;26(6):294‐6. - PubMed
Siniscalchi 2007 {published data only}
    1. Siniscalchi A, Gallelli L, De Sarro G. Combined topiramate and declorazepam therapy in a patient affected by essential tremor. Parkinsonism & Related Disorders 2007;13(2):129‐30. - PubMed
Zesiewicz 2007b {published data only}
    1. Zesiewicz TA. Low‐dose topiramate (Topamax) in the treatment of essential tremor. Clinical Neuropharmacology 2007;30(4):247‐8. - PubMed

Additional references

Bain 1997
    1. Bain PG. The effectiveness of treatments for essential tremor. Neurology 1997;3:305‐21.
Bain 1998
    1. Bain PG. Clinical measurement of tremor. Movement Disorders 1998;13 Suppl 3:77‐80. - PubMed
Bain 2000a
    1. Bain P, Brin M, Deuschl G, Elble R, Jankovic J, Findley L, et al. Criteria for the diagnosis of essential tremor. Neurology 2000;54 Suppl 4:7. - PubMed
Bain 2000b
    1. Bain PG. Tremor assessment and quality of life measurements. Neurology 2000;54 Suppl 4:26‐9. - PubMed
Bialer 2004
    1. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (Eilat VII). Epilepsy Research 2004;61:1‐48. - PubMed
Busenbark 1991
    1. Busenbark KL, Nash J, Nash S, Hubble JP, Koller WC. Is essential tremor benign?. Neurology 1991;41:1982‐3. - PubMed
Chouinard 1997
    1. Chouinard S, Luois ED, Fahn S. Agreement among movement disorder specialists on the clinical diagnosis of essential tremor. Movement Disorders 1997;12(6):973‐6. - PubMed
Connor 2002
    1. Connor GS. A double‐blind placebo‐controlled trial of topiramate treatment for essential tremor. Neurology 2002;59(1):132‐4. - PubMed
Deuschl 1998
    1. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on tremor. Ad Hoc Scientific Committee. Movement Disorders 1998;13 Suppl 3:2‐23. - PubMed
Deuschl 2000
    1. Deuschl G, Koller WC. Essential tremor. Neurology 2000;54 Suppl 4:1. - PubMed
Elble 2013
    1. Elble R, Bain P, Forjaz MJ, Haubenberger D, Testa C, Goetz CG, et al. Task Force Report: scales for screening and evaluating tremor. Critique and recommendations. Movement Disorders 2013;28(13):1793‐800. - PubMed
Fahn 1993
    1. Fahn S, Tolosa E, Marin C. Clinical rating scale for tremor. In: Jankovic J, Tolosa E editor(s). Parkinson' s Disease and Movement Disorders. Baltimore: Williams & Wilkins, 1993:225‐34.
Findley 1995
    1. Findley LJ, Koller W. Definitions and behavioural classifications. In: Findley LG, Koller W editor(s). Handbook of Tremor Disorders. New York: Dekker, 1995:1‐5.
GRADEpro [Computer program]
    1. Schünemann H, Brożek J, Guyatt G, Oxman A. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) profile (pro) and Guideline development tool (GDT). Version 3.6. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Haerer 1992
    1. Haerer AF, Anderson DW, Schoenberg BS. Prevalence of essential tremor: results from the Copiah county study. Archives of Neurology 1992;39:750‐1. - PubMed
Hansten 2004
    1. Hansten PD, Horn JR. In: Wickersham RM, O’Dell, JA editor(s). Managing Clinically Important Drug Interactions. St Louis: Facts & Comparisons, 2004.
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Huber 1988
    1. Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. Neurology 1988;38:241‐3. - PubMed
Hulihan 2003
    1. Hulihan J, Connor GS, Shu‐Chen W. Topiramate in essential tremor: pooled data from a double‐blind, placebo‐controlled, crossover trial. American Academy of Neurology 2003;Abstracts:P04.068.
Jankovic 1996
    1. Jankovic J, Schwartz K, Clemence J. A randomized, double‐blind, placebo controlled study to evaluate botulinum toxin type A in essential tremor. Movement Disorders 1996;11:250‐6. - PubMed
Jankovic 2002
    1. Jankovic J. Essential tremor: a heterogeneous disorder. Movement Disorders 2002;17:638‐44. - PubMed
Koller 1986
    1. Koller W, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology 1986;36:1001‐4. - PubMed
Koller 1989
    1. Koller WC, Vetere‐Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology 1989;39:1587‐8. - PubMed
Kralic 2005
    1. Kralic JE, Criswell HE, Osterman JL, O'Buckley TK, Wilkie ME, Matthews DB, et al. Genetic essential tremor in gamma‐aminobutyric acid A receptor alpha1 subunit knockout mice. Journal of Clinical Investigation 2005;115:774‐9. - PMC - PubMed
Louis 1998
    1. Louis ED, Ford B, Lee H. Diagnostic criteria for essential tremor. Archives of Neurology 1998;55:823‐8. - PubMed
Louis 2001a
    1. Louis ED. Clinical practice, essential tremor. New England Medical Journal 2001;342(12):887‐91. - PubMed
Louis 2001b
    1. Louis ED, Barnes L, Wendt KJ, Ford B, Sangiorgio M, Tabbal S, et al. A teaching videotape for the assessment of essential tremor. Movement Disorders 2001;16:89‐93. - PubMed
Louis 2005
    1. Louis ED. Essential tremor. Lancet Neurology 2005;4:100‐10. - PubMed
Louis 2010
    1. Louis ED, Ferreira JJ. How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Movement Disorders 2010;25(5):534‐41. - PubMed
Morita 2005
    1. Morita S, Miwa H, Kondo T. Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism & Related Disorders 2005;11:101‐3. - PubMed
Ondo 2000
    1. Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple‐dose, double‐blind, placebo‐controlled trial. Movement Disorders 2000;15(4):678‐82. - PubMed
Ondo 2004
    1. Ondo WG, Jankovic J, Stacy MA. Topiramate for essential tremor. Neurology 2004;62:LBS.004. - PubMed
Pahwa 1998
    1. Pahwa R, Lyons K, Hubble JP, Busenbark K, Rienerth JD, Pahwa A, et al. Double‐blind placebo‐controlled study of gabapentin in essential tremor. Movement Disorders 1998;13:465‐7. - PubMed
Pahwa 2003
    1. Pahwa R, Lyons KE. Essential tremor: differential diagnosis for the development of novel therapeutics. American Journal of Medicine 2003;115:134‐42. - PubMed
Rajput 1984
    1. Rajput AH, Offord KP, Beard CM, Kurland LT. Essential tremor in Rochester, Minnesota: a 45‐year study. Journal of Neurology, Neurosurgery and Psychiatry 1984;47:466‐70. - PMC - PubMed
RevMan 2014 [Computer program]
    1. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Salemi 1994
    1. Salemi G, Savettieri G, Rocca WA, Meneghini F, Saporito V, Morgante L, et al. Prevalence of essential tremor: a door to‐door survey in Terrasini, Sicily. Neurology 1994;44:61‐4. - PubMed
Shank 2000
    1. Shank RP, Gardocki JF, Streeter AJ, Mryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia 2000;41 Suppl 1:3‐9. - PubMed
Shorvon 2005
    1. Shorvon SD. Handbook of Epilepsy Treatment. 2nd Edition. Oxford: Blackwell, 2005.
Sibbald 1998
    1. Sibbald B, Roberts C. Understanding controlled trials: crossover trials. BMJ 1998;316(7146):1719‐20. - PMC - PubMed
Snow 1989
    1. Snow B, Wiens M, Hertzman C, Calne D. A community survey of Parkinson's disease. Canadian Medical Association Journal 1989;141:418‐24. - PMC - PubMed
Stacy 2007
    1. Stacy MA, Elble RJ, Ondo WG, Wu SC, Hulihan J, for the TRS Study Group. Assessment of interrater and intrarater reliability of the Fahn‐Tolosa‐Marin Tremor Rating Scale in essential tremor. Movement disorders 2007;22:833‐8. - PubMed
Sullivan 2004
    1. Sullivan KL, Hauser RA, Zesiewicz TA. Essential Tremor Epidemiology, Diagnosis and Treatment. Philadelphia: Lippincott Williams & Wilkins, 2004. - PubMed
Thompson 1984
    1. Thompson C, Lang A, Parkes JD, Marsden CD. A double‐blind trial of clonazepam in benign essential tremor. Clinical Neuropharmacology 1984;7:83‐8. - PubMed
Ueda 2003
    1. Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Molecular Brain Research 2003;116:1‐6. - PubMed
Wasielewski 1998
    1. Wasielewski PG, Burns JM, Koller WC. Pharmacologic treatment of tremor. Movement Disorders 1998;13 Suppl 3:90‐100. - PubMed
White 2003
    1. White HS. Mechanism of action of newer anticonvulsants. Journal of Clinical Psychiatry 2003;62 Suppl 8:5‐8. - PubMed
White 2005
    1. White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005;45:48‐56. - PubMed
Yoshida 2005
    1. Yoshida S, Okada M, Zhu G, Kaneko S. Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors. Epilepsy Research 2005;67:153‐62. - PubMed
Zappia 2013
    1. Zappia M, Albanese A, Bruno E, Colosimo C, Filippini G, Martinelli P, et al. Italian Movement Disorders Association (DISMOV‐SIN) Essential Tremor Committee. Treatment of essential tremor: a systematic review of evidence and recommendations from the Italian Movement Disorders Association. Journal of Neurology 2013;260(3):714‐40. - PubMed
Zesiewicz 2002
    1. Zesiewicz TA, Encarnacion E, Hauser RA. Management of essential tremor. Current Neurology and Neuroscience Reports 2002;2:324‐30. - PubMed
Zesiewicz 2005
    1. Zesiewicz TA, Elble R, Louis ED, Hauser RA, Sullivan KL, Dewey RB Jr, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005;64(12):2008‐20. - PubMed
Zesiewicz 2007a
    1. Zesiewicz TA, Ward CL, Hauser RA, Sanchez‐Ramos J, Staffetti JF, Sullivan KL. A double‐blind placebo‐controlled trial of zonisamide (Zonegran) in the treatment of essential tremor. Movement Disorders 2007;22:279‐82. - PubMed
Zesiewicz 2011
    1. Zesiewicz TA, Elble RJ, Louis ED, Gronseth GS, Ondo WG, Dewey RB Jr, et al. Evidence‐based guideline update: treatment of essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2011;77(19):1752‐5. - PMC - PubMed

MeSH terms

LinkOut - more resources